Cart
sales@molnova.com
BS-181 hydrochloride
CAS No. 1397219-81-6
BS-181 hydrochloride ( BS181 )
Catalog No. M11657 CAS No. 1397219-81-6
BS-181 is a potent, selective CDK7 inhibitor with IC50 of 21 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 40 | In Stock |
|
| 5MG | 65 | In Stock |
|
| 10MG | 115 | In Stock |
|
| 25MG | 259 | In Stock |
|
| 50MG | 430 | In Stock |
|
| 100MG | 620 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameBS-181 hydrochloride
-
NoteResearch use only, not for human use.
-
Brief DescriptionBS-181 is a potent, selective CDK7 inhibitor with IC50 of 21 nM.
-
DescriptionBS-181 is a potent, selective CDK7 inhibitor with IC50 of 21 nM, 40-fold selectivity over CDK2/cycE and no significant activity against CDK1/cycB, CDK4/cycD1, CDK5/p35NCK, CDK6/cycD1, and CDK9/cycT (IC50>1 uM); promotes cell cycle arrest and inhibits cancer cell growth in a panel of cell lines representing a range of tumor types (IC50=1.5 to 37 uM), inhibits the phosphorylation of CDK7 substrates, inhibits phosphorylation of the RNA polymerase II COOH-terminal domain (CTD) at P-Ser5 (IC50=9 uM), inhibits RB phosphorylation at Ser795 and Ser821 (IC50=15 uM); induces apoptosis in vitro, and shows antitumor effects in vivo.
-
SynonymsBS181
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorCDK7
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number1397219-81-6
-
Formula Weight417.00
-
Molecular FormulaC22H33ClN6
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESCl.CC(C)C1=C2N=C(NCCCCCCN)C=C(NCC3=CC=CC=C3)N2N=C1 |c:3,21,23,28,t:5,15,19|
-
Chemical NamePyrazolo[1,5-a]pyrimidine-5,7-diamine, N5-(6-aminohexyl)-3-(1-methylethyl)-N7-(phenylmethyl)-, hydrochloride (1:1)
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Ali S, et al. Cancer Res. 2009 Aug 1;69(15):6208-15.
2. Kelso TW, et al. Mol Cell Biol. 2014 Oct 1;34(19):3675-88.
3. Wang BY, et al. Drug Des Devel Ther. 2016 Mar 16;10:1181-9.
4. Li B, et al. Cancer Res. 2017 Jul 15;77(14):3834-3845.
2. Kelso TW, et al. Mol Cell Biol. 2014 Oct 1;34(19):3675-88.
3. Wang BY, et al. Drug Des Devel Ther. 2016 Mar 16;10:1181-9.
4. Li B, et al. Cancer Res. 2017 Jul 15;77(14):3834-3845.
molnova catalog
related products
-
NU-6027
NU-6027 (NU6027) is an ATP-competitive inhibitor of CDK1 and CDK2 with Ki of 2.5 uM and 1.3 uM respectively.
-
BAY-958
BAY-958 (BAY958, LDC526)is a potent, selective PTEFb/CDK9 inhibitor with IC50 of 5 nM against CDK9/CyclinT1.
-
NU-6300
NU-6300 is the first covalent, irreversible, ATP-Competitive CDK2 inhibitor with Ki of 6 nM.
